23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ACLARIS THERAPEUTICS INC. › 2023-2024

ACLARIS THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 106Asset managers, any item
  • 510Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 4 items on ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (35.6% against).

Notable dissent: 1 other board item (35.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 8.0%, as of September 30, 2026) · BML Capital (13F, 6.9%, as of September 30, 2026)

Explore ACLARIS THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ACLARIS THERAPEUTICS INC.

These tallies are ACLARIS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ACLARIS THERAPEUTICS INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Christopher Molineaux 29,165,764---- 16,154,87712,468,248 64%Passed (calculated)—
Elect Director: Vincent Milano 42,267,754---- 3,052,88712,468,248 93%Passed (calculated)—
2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement 29,025,58316,273,81621,242 --12,468,248 64%Approved—
3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 56,610,6431,154,62423,622 ---- 98%Approved—

Source: ACLARIS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the ACLARIS THERAPEUTICS INC. 2023-2024 meeting

106 asset managers disclosed a vote on at least one ACLARIS THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Christopher Molineaux

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD
FOR: 29,165,764WITHHELD: 16,154,877
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Christopher Molineaux

ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Christopher Molineaux”): 29,165,764 for, 16,154,877 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 7,104,668 for, 3,788,377 withheld, 38,352 abstained.

FORWITHHOLD
FOR: 7,104,668ABSTAIN: 38,352WITHHOLD: 3,788,377
Largest asset managers voting on “Election of Directors: Christopher Molineaux” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,882,1720 00For
BlackRock00 02,706,426Withhold
Fidelity2,114,2160 00For
Charles Schwab00 0419,704Withhold
Equitable00 0186,273Withhold
QUANTITATIVE MASTER SERIES LLC00 0115,378Withhold
TIAA00 097,857Withhold
Lincoln Financial00 057,200Withhold
Pacific Life25,1120 022,969Mixed
T. Rowe Price47,4420 00For
AIG/SunAmerica00 034,229Withhold
Harbor ETF Trust30,3040 00For
State Street00 024,620Withhold
Nationwide00 021,071Withhold
Blackstone Alternative Investment Funds00 016,300Withhold
Principal Exchange-Traded Funds00 016,142Withhold
ProShares00 015,939Withhold
SEI00 015,900Withhold
John Hancock00 14,7880Abstain
Bridge Builder Trust00 12,6530Abstain
DWS00 010,759Withhold
Jackson National00 8,8810Abstain
Principal00 08,732Withhold
Calvert00 06,900Withhold
Guardian Variable Products Trust4,4000 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Elect Director: Vincent Milano

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 42,267,754WITHHELD: 3,052,887
Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Vincent Milano

ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Vincent Milano”): 42,267,754 for, 3,052,887 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 10,857,249 for, 63,237 withheld, 10,911 abstained.

FOR
FOR: 10,857,249ABSTAIN: 10,911WITHHOLD: 63,237
Largest asset managers voting on “Election of Directors: Vincent Milano” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,882,1720 00For
BlackRock2,706,4260 00For
Fidelity2,114,2160 00For
Charles Schwab419,7040 00For
Equitable125,8730 060,400Mixed
QUANTITATIVE MASTER SERIES LLC115,3780 00For
TIAA97,8570 00For
Lincoln Financial57,2000 00For
Pacific Life48,0810 00For
T. Rowe Price47,4420 00For
AIG/SunAmerica34,2290 00For
Harbor ETF Trust30,3040 00For
State Street24,6200 00For
Nationwide21,0710 00For
Blackstone Alternative Investment Funds16,3000 00For
Principal Exchange-Traded Funds16,1420 00For
ProShares15,9390 00For
SEI15,9000 00For
John Hancock14,7880 00For
Bridge Builder Trust12,6530 00For
DWS10,7590 00For
Jackson National00 8,8810Abstain
Principal8,7320 00For
Calvert6,9000 00For
Guardian Variable Products Trust4,4000 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

The compensation of the Company's named executive officers, as disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

64% Approved · of votes cast

FOR 64%AGAINST
FOR: 29,025,583AGAINST: 16,273,816

Prior year: 97.9% for (June 1, 2023 meeting) ▼ 33.9 pts

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.

ACLARIS THERAPEUTICS INC.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 29,025,583 for, 16,273,816 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 34 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,882,1720 00For
BlackRock02,706,426 00Against
Fidelity625,7661,488,450 00Mixed
Charles Schwab0419,704 00Against
Equitable0186,273 00Against
QUANTITATIVE MASTER SERIES LLC0115,378 00Against
TIAA097,857 00Against
Lincoln Financial57,2000 00For
Pacific Life25,11222,969 00Mixed
T. Rowe Price047,442 00Against
AIG/SunAmerica034,229 00Against
Harbor ETF Trust30,3040 00For
State Street24,6200 00For
Nationwide021,071 00Against
Blackstone Alternative Investment Funds016,300 00Against
Principal Exchange-Traded Funds016,142 00Against
ProShares015,939 00Against
SEI015,900 00Against
John Hancock014,788 00Against
Bridge Builder Trust012,653 00Against
DWS010,759 00Against
Jackson National08,881 00Against
Principal08,732 00Against
Calvert06,900 00Against
Guardian Variable Products Trust4,4000 00For

Fund voting reports, all 34 managers: 5,652,947 for, 5,275,613 against, 2,837 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 80 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Bain Capital Life Sciences Investors, LLC3,000,0000 00For
DE Shaw02,857,900 00Against
Rock Springs Capital Management LP2,753,4950 00For
Two Sigma01,726,873 00Against
GEODE CAPITAL MANAGEMENT, LLC01,565,250 00Against
BlackRock13,9291,449,460 00Against
State Street1,132,47516,861 00For
ACADIAN ASSET MANAGEMENT LLC0700,735 00Against
Samsara BioCapital, LLC696,1710 00For
Fidelity667,0370 00For
Ensign Peak Advisors, Inc641,6430 00For
Palo Alto Investors LP569,8320 00For
Northern Trust541,8223,742 00For
Charles Schwab0419,704 00Against
Citadel393,9930 00For
MELLON INVESTMENTS Corp0345,256 00Against
HighTower Advisors, LLC0300,990 00Against
PNC BANK, NATIONAL ASSOCIATION0270,000 00Against
STRS OHIO0264,700 00Against
Aisling Capital Management LP196,5130 00For
AQR0182,931 00Against
BBR PARTNERS, LLC180,0000 00For
Vanguard129,0490 00For
T. Rowe Price0109,767 00Against
Connor, Clark & Lunn Investment Management Ltd.0107,345 00Against

Institutional-manager reports, all 80 managers: 10,999,078 for, 10,949,394 against. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 56,610,643AGAINST: 1,154,624

Prior year: 100.0% for (June 1, 2023 meeting) ▼ 2.0 pts

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2024.

ACLARIS THERAPEUTICS INC.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024”): 56,610,643 for, 1,154,624 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 10,928,560 for, 2,837 abstained.

FOR
FOR: 10,928,560ABSTAIN: 2,837
Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard4,882,1720 00For
BlackRock2,706,4260 00For
Fidelity2,114,2160 00For
Charles Schwab419,7040 00For
Equitable186,2730 00For
QUANTITATIVE MASTER SERIES LLC115,3780 00For
TIAA97,8570 00For
Lincoln Financial57,2000 00For
Pacific Life48,0810 00For
T. Rowe Price47,4420 00For
AIG/SunAmerica34,2290 00For
Harbor ETF Trust30,3040 00For
State Street24,6200 00For
Nationwide21,0710 00For
Blackstone Alternative Investment Funds16,3000 00For
Principal Exchange-Traded Funds16,1420 00For
ProShares15,9390 00For
SEI15,9000 00For
John Hancock14,7880 00For
Bridge Builder Trust12,6530 00For
DWS10,7590 00For
Jackson National8,8810 00For
Principal8,7320 00For
Calvert6,9000 00For
Guardian Variable Products Trust4,4000 00For

Showing the 25 largest of 34 asset managers. All 34 are in the interactive database (link above).

Largest ACLARIS THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,264,786 shares outstanding at the time of that meeting.

Fund voting reports: top ACLARIS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 6.85%
2BlackRock 3.80%
3Fidelity 2.97%
4Charles Schwab 0.59%
5Equitable 0.26%
6QUANTITATIVE MASTER SERIES LLC 0.16%
7TIAA 0.14%
8Lincoln Financial 0.08%
9Pacific Life 0.07%
10T. Rowe Price 0.07%
Institutional-manager reports: top ACLARIS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#Asset manager % of shares outstanding
1Bain Capital Life Sciences Investors, LLC 4.21%
2DE Shaw 4.01%
3Rock Springs Capital Management LP 3.86%
4Two Sigma 2.42%
5GEODE CAPITAL MANAGEMENT, LLC 2.20%
6BlackRock 2.05%
7State Street 1.61%
8ACADIAN ASSET MANAGEMENT LLC 0.98%
9Samsara BioCapital, LLC 0.98%
10Fidelity 0.94%

Reported ACLARIS THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ACLARIS THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vivo Opportunity Fund Holdings, L.P.7,955,160 11.16%Schedule 13G, filed November 21, 2024
Vanguard Group6,515,458 9.14%Form 13F, quarter ended March 31, 2024
BlackRock5,691,352 7.99%Form 13F, quarter ended March 31, 2024
Morgan Stanley4,077,246 5.72%Form 13F, quarter ended March 31, 2024
D.E. Shaw3,282,982 4.61%Form 13F, quarter ended March 31, 2024
Millennium Management3,273,492 4.59%Form 13F, quarter ended March 31, 2024
Renaissance Technologies1,673,400 2.35%Form 13F, quarter ended March 31, 2024
Geode Capital1,565,054 2.20%Form 13F, quarter ended March 31, 2024
State Street1,338,439 1.88%Form 13F, quarter ended March 31, 2024
Two Sigma1,329,616 1.87%Form 13F, quarter ended March 31, 2024

Percentages above are of 71,264,786 shares outstanding, as reported by ACLARIS THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ACLARIS THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 106 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 510 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — ACLARIS THERAPEUTICS INC.'s filing reports the proposal as approved, with 64% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ACLARIS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACLARIS THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ACLARIS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ACLARIS THERAPEUTICS (ACRS) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aclaris-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.